STOCK TITAN
  1. Home
  2. Sec-filings
  3. GH
  4. [Form 4] Guardant Health, Inc. Insider Trading Activity

Guardant Health Strengthens Board Compensation with New Equity Grants

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Director Manuel Hidalgo Medina of Guardant Health [GH] received new equity compensation grants on June 18, 2025, consisting of:

  • Stock Options: Granted 6,833 options to buy common stock at an exercise price of $50.57, which vest fully on June 18, 2026 or the next annual stockholders meeting, whichever occurs first. The options expire on June 18, 2035.
  • Restricted Stock Units (RSUs): Awarded 4,203 RSUs that vest fully on June 18, 2026 or the next annual stockholders meeting, whichever occurs first.

This Form 4 filing, submitted by attorney-in-fact John G. Saia on June 20, 2025, represents standard director compensation equity grants. The combined awards suggest continued board engagement and alignment with shareholder interests through both performance-based options and time-vested RSUs.

Positive

  • None.

Negative

  • None.
Insider Hidalgo Medina Manuel
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 6,833 $0.00 --
Grant/Award Restricted Stock Units 4,203 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 6,833 shares (Direct); Restricted Stock Units — 4,203 shares (Direct)
Footnotes (1)
  1. The stock option vests in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier. The restricted stock units vest in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier. Not applicable for Restricted Stock Units.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hidalgo Medina Manuel
(Last) (First) (Middle)
3100 HANOVER STREET
(Street)
PALO ALTO CA 94304
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $50.57 06/18/2025 A 6,833 (1) 06/18/2035 Common Stock 6,833 $0 6,833 D
Restricted Stock Units $0 06/18/2025 A 4,203 (2) (3) Common Stock 4,203 $0 4,203 D
Explanation of Responses:
1. The stock option vests in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier.
2. The restricted stock units vest in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier.
3. Not applicable for Restricted Stock Units.
Remarks:
/s/ John G. Saia, as attorney-in-fact for Manuel Hidalgo Medina 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What stock options did GH director Manuel Hidalgo Medina receive on June 18, 2025?

Manuel Hidalgo Medina received 6,833 stock options with an exercise price of $50.57. These options will fully vest on June 18, 2026 (one-year anniversary) or the date of the next annual stockholders meeting, whichever comes earlier. The options expire on June 18, 2035.

How many Restricted Stock Units (RSUs) were granted to GH's director Hidalgo Medina?

Manuel Hidalgo Medina was granted 4,203 Restricted Stock Units (RSUs) on June 18, 2025. These RSUs will vest in full on the one-year anniversary of the grant date (June 18, 2026) or the date of the next annual stockholders meeting, whichever occurs earlier.

What is the vesting schedule for GH director Hidalgo Medina's June 2025 equity grants?

Both the stock options and RSUs granted to Hidalgo Medina follow the same vesting schedule: they vest 100% on the one-year anniversary of the grant date (June 18, 2026) or the date of the next annual stockholders meeting, whichever comes first.

What is the total value of equity compensation awarded to GH director Manuel Hidalgo Medina in June 2025?

The Form 4 shows that Hidalgo Medina received two equity awards: 6,833 stock options with a strike price of $50.57 and 4,203 Restricted Stock Units (RSUs) with a $0 exercise price. The RSUs represent direct share equivalents, while the options' value would depend on GH's stock price appreciation above $50.57.